Clinical Trials Logo

Relapsed/Refractory AML clinical trials

View clinical trials related to Relapsed/Refractory AML.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01319864 Completed - AML Clinical Trials

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

Start date: March 2011
Phase: Phase 1
Study type: Interventional

In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs—cytarabine and etoposide. We want to find out what effects, good and /or bad, this combination of drugs has on leukemia. Plerixafor is a drug that blocks a receptor on the leukemia cell, which prevents it from staying in the bone marrow where it can be resistant to chemotherapy. Plerixafor is FDA approved for mobilizing stem cells from the bone marrow in preparation for an autologous stem cell transplant. Cytarabine and etoposide have been used as part of standard chemotherapy for ALL and AML. However, the use of plerixafor with cytarabine and etoposide in pediatric patients with relapsed or refractory ALL, AML and MDS is considered experimental.

NCT ID: NCT01258816 Completed - Clinical trials for Relapsed/Refractory AML

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the pharmacokinetics (PK) and cardiac properties of elacytarabine in patients with relapsed or refractory Acute Myeloid Leukaemia (AML). The efficacy and tolerability of elacytarabine will also be assessed.